Diamyd Medical (Sweden) Investor Sentiment

DMYD-B Stock  SEK 12.74  0.18  1.39%   
About 61% of Diamyd Medical's investor base is looking to short. The analysis of current outlook of investing in Diamyd Medical AB suggests that many traders are alarmed regarding Diamyd Medical's prospects. The current market sentiment, together with Diamyd Medical's historical and current headlines, can help investors time the market. In addition, many technical investors use Diamyd Medical AB stock news signals to limit their universe of possible portfolio assets.
  
over a year ago at news.google.com         
Less than half of endocrinologists are impressed with Tzields ability ... - PR Newswire
Google News at Macroaxis
over a year ago at news.google.com         
Diamyd Medical announces final outcome in the companys rights issue - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Bulletin from Extra General Meeting of Diamyd Medical AB - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Diamyd Medical refrains from enforcing the underwriting ... - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Diamyd Medical provides an update regarding the ongoing new share issue - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Trading in subscription rights in Diamyd Medicals rights issue halted - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Diamyd Medical provides supplementary information about the upcoming Extraordinary General Meeting -...
Google News at Macroaxis
over a year ago at news.google.com         
Diamyd Medical resolves on a rights issue of shares of approximately SEK 163 million and convenes an...
Google News at Macroaxis
over a year ago at news.google.com         
Topline results from Remygen trial in individuals with long-term Type 1 Diabetes - Marketscreener.co...
Google News at Macroaxis
over a year ago at news.google.com         
Insiders of Diamyd Medical AB forfeit last weeks 22 percent gains after selling stock earlier this y...
Google News at Macroaxis
over a year ago at news.google.com         
Diamyd Medical partners with JDRF to advance the DIAGNODE-3 Phase 3 trial in Type 1 Diabetes - Marke...
Google News at Macroaxis
over a year ago at news.google.com         
Remygen trial results to be presented in April - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Appointments and advancements for March 10, 2023 - BioWorld Online
Google News at Macroaxis
over a year ago at news.google.com         
Diamyd Medical Brings Karin Rosn to Its Board of Directors - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Patient recruitment for the pivotal Diamyd Phase 3 trial is progressing according to plan - Marketsc...
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Diamyd Medical that are available to investors today. That information is available publicly through Diamyd media outlets and privately through word of mouth or via Diamyd internal channels. However, regardless of the origin, that massive amount of Diamyd data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Diamyd Medical news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Diamyd Medical relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Diamyd Medical's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Diamyd Medical alpha.

Diamyd Medical Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Diamyd Stock analysis

When running Diamyd Medical's price analysis, check to measure Diamyd Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Diamyd Medical is operating at the current time. Most of Diamyd Medical's value examination focuses on studying past and present price action to predict the probability of Diamyd Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Diamyd Medical's price. Additionally, you may evaluate how the addition of Diamyd Medical to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Transaction History
View history of all your transactions and understand their impact on performance
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets